Reprimand for dispensing overprescribed medicines
The Royal Pharmaceutical Society’s Disciplinary Committee has
reprimanded a Bedfordshire pharmacist for misconduct in dispensing medicines
that had been inadvertently prescribed in excessive quantities.
At a hearing which began in August 2007 and concluded on 28 September
2007, the committee inquired into a complaint by the Council of the Society
against Adegboyega Bolarinwa Claudius Salako (registration number 66018)
of Luton. The Council alleged that Mr Salako was guilty of misconduct
in that during 2002 and 2003 he had supplied a patient with excessive
quantities of glyceryl trinitrate (GTN), Didronel PMO and Oramorph from
the pharmacy he then owned in Luton. In doing so, the Council alleged,
he had infringed key responsibility 1 of the Society’s then code
of ethics, which required pharmacists, among other things, to act at
all times in the interests of patient and to seek to provide the best
possible healthcare.
The Council alleged that between about 30 July 2002 and 15 May 2003 Mr
Salako had dispensed 18 prescriptions each calling for one GTN 400µg
spray, which contained about 200 doses; between about 18 February 2002
and 24 April 2003, he had dispensed about 24 prescriptions each calling
for one 90-day course of Didronel PMO tablets; and between about 30 May
and 30 September 2002 he had dispensed 10 prescriptions each calling
for 200ml Oramorph oral solution. For each drug, up to four prescriptions
had been raised on the same date, but Mr Salako had made inadequate efforts
to query the excessive quantities with the prescribers.
In evidence to the committee, three prescribing doctors said that the
excessive quantities had been prescribed because the prescriptions were
computer-generated and had not been adequately checked when they were
signed. However, in the case of the Oramorph prescriptions, the doctor
who most often attended the patient said that the quantities prescribed
and supplied were not out of the ordinary.
Giving the committee’s determination, the chairman, John Burrow,
said that the committee found breaches of key responsibility 1 in respect
of GTN and Didronel PMO prescriptions but not in respect of Oramorph.
The supplies were lawful in that they were made in response to genuine
prescriptions and there was no allegation of unjust enrichment or dishonesty,
but even so Mr Salako’s dispensing was seriously deficient. The
pharmacist’s duty to check prescriptions and resolve queries with
the prescriber was an important one for the protection of the patient.
The committee concluded that the breach of the code was serious enough
to render Mr Salako unfit to remain on the Register of Pharmaceutical
Chemists.
However, there were a number of mitigating factors, including Mr Salako’s
insight into the matter, his attempts to remedy the situation, the small
financial gain and the fact that the errors were initiated by others.
The committee did not think there was a continued risk to the public
or that the matters were so serious as to undermine confidence in the
profession. A reprimand was, therefore, the appropriate and proportionate
sanction.
Back to Top
|